Showing 15 posts of 46 posts found.


Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

May 12, 2023
Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …


Epilepsy drug receives MHRA marketing authorisation

June 17, 2021
MHRA, epilepsy, marketing authorisation

The MHRA has granted marketing authorisation (MA) for Ontozry (cenobamate) for the treatment of focal-onset seizures in adult patients with …

Accure Therapeutics’ drug candidate can slow epilepsy progression, study shows

February 10, 2021
Research and Development epilepsy

Accure Therapeutics, an R&D pharmaceutical company in the central nervous system (CNS) field, has announced the publication of a pivotal …

EMA recommends Arvelle’s seizure drug cenobamate

February 2, 2021
Manufacturing and Production Arvelle Therapeutics, epilepsy

The EMA has recommended the approval of Arvelle Therapeutics’ cenobamate for the adjunctive treatment of focal onset seizures with or …


NHS guidelines on prescription cannabis to be challenged in court

August 18, 2020
Manufacturing and Production, Research and Development CBD, cannabis, epilepsy

The cannabis guidelines followed by the NHS are set to be challenged in court by the parents of a three-year-old …

EMA gives market authorisation application to epilepsy treatment from Arvelle Therapeutics

March 30, 2020
Sales and Marketing EMA, EMA approvals, approvals, epilepsy

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for a cenobamate adjunctive treatment of focal-onset seizures …


Idorsia reveals it is working with Neurocrine on new epilepsy drug deal

January 10, 2020
Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …


NHS to fast track cannabis-based treatment for epilepsy

December 23, 2019
Sales and Marketing CBD, CBD Oil, cannabis, drug treatment, epilepsy, thc

The NHS has fast-tracked the drug Epidyolex, a cannabidiol (CBD), to be available for epilepsy treatment through the NHS in …


China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019
Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …


GW Pharma’s cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy

July 26, 2019
Medical Communications, Sales and Marketing EMA, Epidiolex, Europe, GW Pharma, cannabis, epilepsy

UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s …

Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures

May 28, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure

Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …


GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial

May 7, 2019
Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc

GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …


Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues

April 9, 2019
Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma

The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …


Antiepileptics increase the risk of pneumonia in people with Alzheimer’s disease

March 21, 2019
Research and Development Alzheimer's, R&D, adverse events, antiepileptic drugs, epilepsy, pneumonia

Antiepileptic drugs increase the risk of pneumonia in people living with Alzheimer’s disease, according to research from the University of …

UCB teams up with charity to beat treatment-resistant epilepsy in $2.5m partnership

February 11, 2019
Research and Development, Sales and Marketing Epilepsy Society, UCB Pharma, epilepsy, pharma

Belgian firm UCB Pharma has announced a new partnership with the charity Epilepsy Society which will see the pair invest …

Latest content